Alpha-synuclein expression stabilizes the proteasome activator Blm10/PA200, enabling a specialized proteasome configuration that efficiently degrades both monomeric and oligomeric alpha-synuclein while remaining resistant to proteasome inhibition. This mechanism maintains protein degradation capacity under proteotoxic stress conditions characteristic of Parkinson's disease.
Key Points
- Blm10/PA200-capped 20S proteasomes resist alpha-synuclein-induced inhibition
- Alpha-synuclein stabilizes Blm10 through S129 phosphorylation-dependent autophagy inhibition
- Overexpression reduces alpha-synuclein aggregation and enhances clearance in mammalian cells
Longevity Analysis
The capacity to degrade misfolded proteins declines with age, enabling accumulation of toxic aggregates that drive neurodegeneration. This research identifies a previously unrecognized proteasome configuration that maintains proteolytic function precisely when standard degradation pathways become compromised. By establishing Blm10/PA200 as a critical regulator of protein clearance under stress, the work points toward a targetable mechanism for restoring the body's ability to remove damaged proteins—one of the fundamental requirements for sustained neurological function and cellular regeneration across the lifespan.
Original published by Wiley Aging Cell, by Tariq T. Ali, Anton Zhornyak, Madiha Merghani, Zora Buschenlange, Eri Sakata, Tiago F. Outeiro, Blagovesta Popova, Gerhard H. Braus .